MARK2 and neoplasm: In particular, the emergence of molecular targeted therapies including inhibitors for V600E mutated B-Raf proto-oncogene, serine/threonine kinase (BRAF) and checkpoint inhibitors, which attenuate suppression of the anti-tumor immune response, have drastically improved the outcome of advanced melanoma.